Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Abstract
The selective serotonin reuptake inhibitors (SSRIs) have emerged as a major therapeutic advance in psychopharmacology. As a result, the discovery of these agents marks a milestone in neuropsychopharmacology and rational drug design, and has launched a new era in psychotropic drug development. Prior to the SSRIs, all psychotropic medications were the result of chance observation. In an attempt to develop a SSRI, researchers discovered a number of nontricyclic agents with amine-uptake inhibitory properties, acting on both noradrenergic and serotonergic neurons with considerable differences in potency. A given drug may affect one or more sites over its clinically relevant dosing range and may produce multiple and different clinical effects. The enhanced safety profile includes a reduced likelihood of pharmacodynamically mediated adverse drug-drug interactions by avoiding affects on sites that are not essential to the intended outcome. SSRIs were developed for inhibition of the neuronal uptake pump for serotonin (5-HT), a property shared with the TCAs, but without affecting the other various neuroreceptors or fast sodium channels. The therapeutic mechanism of action of SSRIs involves alteration in the 5-HT system. The plethora of biological substrates, receptors and pathways for 5-HT are candidates to mediate not only the therapeutic actions of SSRIs, but also their side effects. A hypothesis to explain these immediate side effects is that 5-HT is increased at specific 5-HT receptor subtypes in discrete regions of the body where the relevant physiologic processes are regulated. Marked differences exist between the SSRIs with regard to effects on specific cytochrome P450 (CYP) enzymes, and thus the likelihood of clinically important pharmacokinetic drug-drug interactions. Although no clear relationship exists between the clinical efficacy, plasma concentration of SSRIs, nor any threshold that defines toxic concentrations, but therapeutic drug monitoring (TDM) may be useful in special populations, such as in elderly patients, poor metabolizers (PM) of sparteine (CYP2D6) or mephenytoin (CYP2C19), and patients with liver and kidney impairment. Several meta-analyses have reviewed the comparative efficacy of TCAs and SSRIs, and concluded that both TCAs and SSRIs have similar efficacy in the treatment of depression. SSRIs have demonstrated better efficacy and tolerability in the treatment of obsessive compulsive disorder (OCD). They have also been found to be effective in the treatment for social anxiety disorder both in reducing total levels of social anxiety and in improving overall clinical condition. The benefit of SSRIs in anorexia nervosa (AN) is apparently short-term unless medication is given in the context of nutritional or behavioral therapy. No single antidepressant can ever be recommended for every patient, but in a vast majority of patients, SSRIs should be considered as one of the first-line drugs in the treatment of depression.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many of these drugs can acutely induce adverse side effects including anxiety and increased risk of suicidal behaviors.
“However many of these drugs can acutely induce adverse side effects including anxiety and increased risk of suicidal behaviors (Ferguson, 2001; Gartlehner et al., 2011; Vaswani et al., 2003).”
From Molecular and anatomical organization of the dorsal raphe nucleus (2019) · cites this paper as Vaswani et al., 2003
Cites
1 retracted
Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
Geddes, J. R., Freemantle, N., Mason, J. M., Eccles, M., & Boynton, J. R. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001851 · Cited by 109 · see citing works
RetractedKessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370 · see citing works
Comprehensive Textbook of Psychiatry
Freedman, A. M., & Kaplan, H. I. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196712000-00052 · Cited by 3,825 · see citing works
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., & Humphrey, P. P. A. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06783-3 · Cited by 2,997 · see citing works
Sternbach, H. A. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,349 · see citing works
Anderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940 · see citing works
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 887 · see citing works
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 827 · see citing works
Birth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735 · see citing works
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676 · see citing works
Wong, D. T., Bymaster, F. P., & Engleman, E. A. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00209-o · Cited by 647 · see citing works
THE TREATMENT OF DEPRESSIVE STATES WITH G 22355 (IMIPRAMINE HYDROCHLORIDE)
Kuhn, R. (1958) · American Journal of Psychiatry · doi:10.1176/ajp.115.5.459 · Cited by 615 · see citing works
Anatomy of the Serotonergic Systema
Törk, I. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16870.x · Cited by 557 · see citing works
Mechanism of action of serotonin selective reuptake inhibitors
Stahl, S. M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00221-3 · Cited by 540 · see citing works
Emergence of intense suicidal preoccupation during fluoxetine treatment
Teicher, M. H., Glod, C. A., & Cole, J. O. (1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.2.207 · Cited by 534 · see citing works
Benfield, P., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632040-00002 · Cited by 496 · see citing works
Crewe, H. K., Lennard, M., Tucker, G., Woods, F. R., & Haddock, R. E. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 468 · see citing works
(1998) · PubMed · Cited by 460 · see citing works
Systematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors
Edwards, J. G., & Anderson, I. M. (1999) · Drugs · doi:10.2165/00003495-199957040-00005 · Cited by 455 · see citing works
A Review of the Efficacy of Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder
Pigott, T. A., & Seay, S. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0206 · Cited by 455 · see citing works
Fluoxetine in the Treatment of Premenstrual Dysphoria
Steiner, M. S., Steinberg, S. I., Stewart, D. E., Carter, D., Berger, C., Reid, R. L., Grover, D., & Streiner, D. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506083322301 · Cited by 450 · see citing works
Pregnancy Outcome Following Maternal Use of the New Selective Serotonin Reuptake Inhibitors
Kulin, N. A., Pastuszak, A. L., Sage, S. R., Schick-Boschetto, B., Spivey, G., Feldkamp, M. L., Ormond, K. E., Matsui, D. M., Schechtman, A. S., Cook, L. P., et al. (1998) · JAMA · doi:10.1001/jama.279.8.609 · Cited by 423 · see citing works
Bourin, M., Chue, P. S., & Guillon, Y. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00189.x · Cited by 412 · see citing works
Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.
Song, F., Freemantle, N., Sheldon, T. A., House, A., Watson, P., Long, A., & Mason, J. (1993) · BMJ · doi:10.1136/bmj.306.6879.683 · Cited by 399 · see citing works
Danish University Antidepressant Group (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90081-i · Cited by 398 · see citing works
Mehlman, P. T., Higley, J. D., Faucher, I., Lilly, A. A., Taub, D. M., Vickers, J. H., Suomi, S. J., & Linnoila, M. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1485 · Cited by 375 · see citing works
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. H. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374 · see citing works
Hemeryck, A., & Belpaire, F. M. (2002) · Current Drug Metabolism · doi:10.2174/1389200023338017 · Cited by 370 · see citing works
Preskorn, S. H. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00003 · Cited by 370 · see citing works
Movement Disorders Associated With the Serotonin Selective Reuptake Inhibitors
Leo, R. J. (1996) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v57n1002 · Cited by 365 · see citing works
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
Beasley, C. M., Dornseif, B. E., Bosomworth, J. C., Sayler, M. E., Rampey, A. H., Heiligenstein, J. H., Thompson, V. L., Murphy, D. J., & Masica, D. N. (1991) · BMJ · doi:10.1136/bmj.303.6804.685 · Cited by 361 · see citing works
Binding of antidepressants to human brain receptors: focus on newer generation compounds
Cusack, B. M., Nelson, A. N., & Richelson, E. (1994) · Psychopharmacology · doi:10.1007/bf02244985 · Cited by 349 · see citing works
Fluoxetine in post-traumatic stress disorder
Davidson, J. R. T., Roth, S., & Newman, E. (1991) · Journal of Traumatic Stress · doi:10.1007/bf00974559 · Cited by 347 · see citing works
Benfield, P., Heel, R. C., & Lewis, S. P. (1986) · Drugs · doi:10.2165/00003495-198632060-00002 · Cited by 336 · see citing works
Haria, M., Fitton, A., & McTavish, D. (1994) · Drugs & Aging · doi:10.2165/00002512-199404040-00006 · Cited by 331 · see citing works
Preskorn, S. (1995) · PubMed · Cited by 327 · see citing works
Jeppesen, U., Gram, L. F., Vistisen, K. K., Loft, S. H., Poulsen, H. E., & Brøsen, K. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050163 · Cited by 321 · see citing works
Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors
van Harten, J. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324030-00003 · Cited by 311 · see citing works
Clerc, G. E., Ruimy, P., & Verdeau-Pailles, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199409000-00001 · Cited by 301 · see citing works
Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study
Gram, L. F. (1986) · Psychopharmacology · doi:10.1007/bf00172884 · Cited by 301 · see citing works
Wagstaff, A. J., Cheer, S. M., Matheson, A. J., Ormrod, D. J., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262040-00010 · Cited by 289 · see citing works
van Vliet, I. M., den Boer, J. A., & Westenberg, H. G. M. (1994) · Psychopharmacology · doi:10.1007/bf02244762 · Cited by 270 · see citing works
A review of the metabolism and pharmacokinetics of paroxetine in man
Kaye, C. M., Haddock, R. E., Langley, P. F., MELLOWS, G., Tasker, T. C. G., Zussman, B. D., & Greb, W. H. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb07176.x · Cited by 268 · see citing works
Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders
Gerber, P. E., & Lynd, L. D. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17302 · Cited by 267 · see citing works
Pharmacokinetics of antidepressants: why and how they are relevant to treatment.
Cummings, J. L. (1993) · PubMed · Cited by 263 · see citing works
Pharmacology of Antidepressants—Characteristics of the Ideal Drug
Richelson, E. (1994) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61375-5 · Cited by 258 · see citing works
Selective serotonin reuptake inhibitors
Montgomery, S. A., Henry, J. A., McDonald, G. J., Dinan, T. G., LADER, M. H., Hindmarch, I., Clare, A. W., & Nutt, D. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199400910-00008 · Cited by 254 · see citing works
A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder
Black, D. W. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130046008 · Cited by 249 · see citing works
Fluoxetine in post‐traumatic stress disorder
Davidson, J. R. T., Roth, S., & Newman, E. (1991) · Journal of Traumatic Stress · doi:10.1002/jts.2490040309 · Cited by 247 · see citing works
Fluoxetine-induced sexual dysfunction and an open trial of yohimbine.
Jacobsen, F. M. (1992) · PubMed · Cited by 236 · see citing works
Peretti, S., Judge, R., & Hindmarch, I. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10944.x · Cited by 236 · see citing works
Murdoch, D., & McTavish, D. (1992) · Drugs · doi:10.2165/00003495-199244040-00007 · Cited by 233 · see citing works
Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle, S., DaSilva, J., Wilson, A. A., Rafi-Tari, S., Mayberg, H. S., & Kennedy, S. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.78 · Cited by 231 · see citing works
D, M. F. M., Rosenbaum, J. F., Pava, J. A., McCarthy, M. K., Steingard, R., & Bouffides, E. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.8.1158 · Cited by 229 · see citing works
Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors
Zohar, J., & Westenberg, H. G. M. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10947.x · Cited by 218 · see citing works
Multiple Serotonin Receptors: Clinical and Experimental Aspects
Roth, B. L. (1994) · Annals of Clinical Psychiatry · doi:10.3109/10401239409148985 · Cited by 213 · see citing works
Sindrup, S. H., Brøsen, K., Hansen, M. G. J., Aaes‐Jørgensen, T., Overø, K. F., & Gram, L. F. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199302000-00002 · Cited by 213 · see citing works
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis.
Workman, E. A., & Short, D. D. (1993) · PubMed · Cited by 212 · see citing works
Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors???
Baumann, P. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631060-00004 · Cited by 212 · see citing works
Selective Serotonin-Reuptake Inhibitors: An Update
Masand, P. S., & Gupta, S. (1999) · Harvard Review of Psychiatry · doi:10.3109/hrp.7.2.69 · Cited by 211 · see citing works
Clinical and Physiological Consequences of Rapid Tryptophan Depletion
Moore, P. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00161-5 · Cited by 205 · see citing works
Effect of phenytoin on plasma clozapine concentrations in two patients.
Preskorn, S. H., & Fast, G. A. (1991) · PubMed · Cited by 201 · see citing works
Fluoxetine, a selective inhibitor of serotonin uptake
Fuller, R. W., Wong, D. T., & Robertson, D. W. (1991) · Medicinal Research Reviews · doi:10.1002/med.2610110103 · Cited by 197 · see citing works
Kaye, W. H., Gendall, K. A., & Strober, M. A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00195-4 · Cited by 193 · see citing works
Wood, A. J. J., & Gram, L. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312008 · Cited by 192 · see citing works
Feiger, A. D., Kiev, A., Shrivastava, R. K., Wisselink, P., & Wilcox, C. S. (1996) · PubMed · Cited by 185 · see citing works
Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks
Boyer, W. F. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199503000-00006 · Cited by 185 · see citing works
Perry, P. J. (1996) · Journal of Affective Disorders · doi:10.1016/0165-0327(96)00014-6 · Cited by 181 · see citing works
Montgomery, S. A. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90266-o · Cited by 172 · see citing works
PRICE, J. S., WALLER, P. C., WOOD, S. M., & MACKAY, A. V. P. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00498.x · Cited by 171 · see citing works
Hyponatraemia and selective serotonin re‐uptake inhibitors in elderly patients
Kirby, D., & Ames, D. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.367 · Cited by 169 · see citing works
Changes in Weight During a 1-Year Trial of Fluoxetine
Michelson, D., Amsterdam, J. D., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Zajecka, J., Sundell, K. L., Kim, Y., & Beasley, C. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1170 · Cited by 167 · see citing works
Citalopram in Premenstrual Dysphoria
Wikander, I., Sundblad, C., Andersch, B., Dagnell, I., Zylberstein, D. E., Bengtsson, F., & Eriksson, E. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199810000-00007 · Cited by 164 · see citing works
Wheatley, D. P., Moffaert, M. V., Timmerman, L., & Kremer, C. M. E. (1998) · PubMed · Cited by 157 · see citing works
Marshall, R. D., Schneier, F. R., Fallon, B. A., Knight, C., Abbate, L. A., Goetz, D. M., Campeas, R. B., & Liebowitz, M. R. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199802000-00003 · Cited by 154 · see citing works
Noradrenergic function in panic disorder.
Ds, C., Woods, S., Nagy, L. M., Sm, S., Krystal, J. H., & Heninger, G. R. (1990) · PubMed · Cited by 153 · see citing works
Dieric, M., Ravizza, U., Realini, R., & Martin, A. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00292-8 · Cited by 152 · see citing works
Ronfeld, R. A., Tremaine, L. M., & Wilner, K. D. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00004 · Cited by 151 · see citing works
Fluoxetine versus phenelzine in atypical depression
Pande, A. C., Birkett, M. A., Fechner-Bates, S., Haskett, R. F., & Greden, J. F. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00628-1 · Cited by 146 · see citing works
Wheatley, D. P., van Moffaert, M., Timmerman, L., Kremer, C. M. E., & The Mirtazapine-Fluoxetine Study Group (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0606 · Cited by 145 · see citing works
Carlsson, A., & Lindqvist, M. (1969) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1969.tb08287.x · Cited by 136 · see citing works
Kobayashi, K., Chiba, K., Yagi, T., Shimada, N., Taniguchi, T., Horie, T., Tani, M., Yamamoto, T., Ishizaki, T., & Kuroiwa, Y. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36462-6 · Cited by 134 · see citing works
Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
Walker, P. W., Cole, J. O., Gardner, E. A., Hughes, A. R., Johnston, J. A., Batey, S. R., & Lineberry, C. G. (1993) · PubMed · Cited by 132 · see citing works
Fleishaker, J. C., & Hulst, L. K. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00195913 · Cited by 131 · see citing works
Molecular genetics of the human cytochrome P450 monooxygenase superfamily
Smith, G. C., Stubbins, M. J., Harries, L. W., & Wolf, C. R. (1998) · Xenobiotica · doi:10.1080/004982598238868 · Cited by 130 · see citing works
van der Linden, G. J., Stein, D. J., & van Balkom, A. J. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200008002-00004 · Cited by 130 · see citing works
Overview of the Pharmacokinetics of Fluvoxamine
van Harten, J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199500291-00003 · Cited by 129 · see citing works
Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study
Amsterdam, J. D., FAWCETT, J. A., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Michelson, D., Hornig, M., & Beasley, C. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.7.963 · Cited by 127 · see citing works
Rasmussen, B. B., & Brøsen, K. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200004000-00001 · Cited by 125 · see citing works
Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects
Delgado, P. L., Charney, D. S., Price, L. H., LANDIS, H. D., & Heninger, G. R. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90114-8 · Cited by 124 · see citing works
The Selective Serotonin Reuptake Inhibitor Sertraline: Its Profile and Use in Psychiatric Disorders
MacQUEEN, G. M., Born, L., & Steiner, M. S. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00188.x · Cited by 122 · see citing works
Figgitt, D. P., & McClellan, K. J. (2000) · Drugs · doi:10.2165/00003495-200060040-00006 · Cited by 122 · see citing works
Carrillo, J. A., Dahl, M., Svensson, J., Alm, C., Rodríguez, I., & Bertilsson, L. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90134-4 · Cited by 122 · see citing works
Review of the animal pharmacology and pharmacokinetics of fluvoxamine.
Claassen, V. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb02125.x · Cited by 114 · see citing works
Selective Serotonin Reuptake Inhibitors
Mozayani, M. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-222-9_6 · Cited by 113 · see citing works
Pharmacology and pharmacokinetics of citalopram and other SSRIs
Baumann, P. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199603001-00002 · Cited by 113 · see citing works
The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin*
Hamelin, B. A., Turgeon, J., Vallée, F., Bélanger, P.-M., Paquet, F., & LeBel, M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90147-2 · Cited by 112 · see citing works
Montgomery, S. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(94)00131-t · Cited by 111 · see citing works
Rochat, B., Amey, M., Gillet, M., Meyer, U., & Baumann, P. (1997) · Pharmacogenetics · doi:10.1097/00008571-199702000-00001 · Cited by 111 · see citing works
Pharmacokinetics of the newer antidepressants: Clinical relevance
DeVane, C. L. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90359-x · Cited by 110 · see citing works
The treatment of benzodiazepine dependence
ASHTON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03755.x · Cited by 110 · see citing works
Olesen, O. V., & Línnet, K. (1999) · Pharmacology · doi:10.1159/000028333 · Cited by 109 · see citing works
Moltke, L. L., Greenblatt, D. J., Duan, S. X., Schmider, J., Kudchadker, L., Fogelman, S. M., Harmatz, J. S., & Shader, R. I. (1996) · Psychopharmacology · doi:10.1007/s002130050149 · Cited by 107 · see citing works
Guillain-Barre syndrome following zimeldine treatment.
Fagius, J., OSTERMAN, P. O., Sidén, Å., & Wiholm, B. ‐. (1985) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.1.65 · Cited by 107 · see citing works
Schmider, J., Greenblatt, D. J., Moltke, L. L., Karsov, D., & Shader, R. I. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00601.x · Cited by 104 · see citing works
Citalopram: a comprehensive review
Pollock, B. G. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.4.681 · Cited by 102 · see citing works
Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa?
Ferguson, C. P., Via, M. C. L., Crossan, P. J., & Kaye, W. H. (1999) · International Journal of Eating Disorders · doi:10.1002/(sici)1098-108x(199901)25:1 · Cited by 100 · see citing works
The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
FJORDSIDE, L., Jeppesen, U., Eap, C. B., Powell, K., Baumann, P., & Brossen, K. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00008 · Cited by 100 · see citing works
Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors
Lane, R. M. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199612005-00005 · Cited by 98 · see citing works
Fluoxetine-induced sexual dysfunction.
Patterson, W. M. (1993) · PubMed · Cited by 97 · see citing works
Stanford, S. C. (1996) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(96)81591-4 · Cited by 94 · see citing works
Iproniazid (marsilid) phosphate, a therapeutic agent for mental disorders and debilitating diseases.
Crane, G. E. (1957) · PubMed · Cited by 94 · see citing works
Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans
Spigset, O., Carleborg, L., Hedenmalm, K., & Dahlqvist, R. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90052-7 · Cited by 93 · see citing works
Fluvoxamine Treatment for Chronic PTSD: A Pilot Study
Boer, M. D., den Velde, W. O., Falger, P. R. J., Hovens, J. E. J. M., de Groen, J. H. M., & van Duijn, H. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000288593 · Cited by 93 · see citing works
Drug-Metabolizing Enzymes and Therapeutic Drug Monitoring in Psychiatry
Brøsen, K. (1996) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199608000-00014 · Cited by 92 · see citing works
Therapeutic Drug Monitoring of Antidepressants
Burke, M. J., & Preskorn, S. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937020-00004 · Cited by 91 · see citing works
Selective Serotonin Reuptake Inhibitors for Late-Life Depression
Solai, L. K., Mulsant, B. H., & Pollock, B. G. (2001) · Drugs & Aging · doi:10.2165/00002512-200118050-00006 · Cited by 90 · see citing works
Sertraline 50 mg daily: the optimal dose in the treatment of depression
Preskorn, S., & Lane, R. M. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199510030-00001 · Cited by 90 · see citing works
Rapid cycling depression in adolescence
Spurkland, I., & Vandvik, I. H. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb01300.x · Cited by 89 · see citing works
Simultaneous panic and depressive disorder: response to antidepressant treatments.
Grunhaus, L. J., Rabin, D. M., & Greden, J. F. (1986) · PubMed · Cited by 88 · see citing works
Human cytochromes mediating N -demethylation of fluoxetine in vitro
Moltke, L. L., Greenblatt, D. J., Duan, S. X., Schmider, J., Wright, C. E., Harmatz, J. S., Shader, R. I., & Moltke, L. L. (1997) · Psychopharmacology · doi:10.1007/s002130050362 · Cited by 86 · see citing works
Spina, E., Avenosoa, A., Facciolá, G., Fabrazzo, M., Monteleone, P., Maj, M., Perucca, E., & Caputi, A. R. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199805000-00009 · Cited by 84 · see citing works
Lönnqvist, J. K., Sintonen, H., Syvälahti, E. K. G., Appelberg, B., Koskinen, T., Männikkö, T., Mehtonen, O. ‐., Naarala, M., Sihvo, S., AUVINEN, J. P., et al. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01530.x · Cited by 80 · see citing works
Serotonin-Specific Drugs for Anxiety and Depressive Disorders
Charney, D. S., Krystal, J. H., Delgado, P. L., & Heninger, G. R. (1990) · Annual Review of Medicine · doi:10.1146/annurev.me.41.020190.002253 · Cited by 80 · see citing works
Baldwin, D. S., Hawley, C. J., Abed, R. T., Maragakis, B. P., Cox, J. L., Buckingham, S. A., Pover, G. H., & Ascher, A. (1996) · PubMed · Cited by 79 · see citing works
Kobayashi, K., Yamamoto, T., Chiba, K., Tani, M., Ishizaki, T., & Kuroiwa, Y. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05793.x · Cited by 78 · see citing works
Silver, H., & Shmugliakov, N. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199806000-00005 · Cited by 77 · see citing works
Citalopram in the treatment of obsessive‐compulsive disorder: an open pilot study
Koponen, H., Lepola, U. M., Leinonen, E. V. J., Jokinen, R., Penttinen, J., & Turtonen, J. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09927.x · Cited by 75 · see citing works
Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients
Härtter, S., Wetzel, H., Hammes, E., & Hiemke, C. (1993) · Psychopharmacology · doi:10.1007/bf02251285 · Cited by 73 · see citing works
COMBINING PHARMACOTHERAPY AND PSYCHOTHERAPY IN THE TREATMENT OF PATIENTS WITH EATING DISORDERS
Mitchell, J. E., Peterson, C. B., Myers, T. C., & Wonderlich, S. A. (2001) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70227-6 · Cited by 73 · see citing works
Kasper, S. F., Dötsch, M., Kick, H. A., Vieira, A. H. G., & Möller, H.-J. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90290-3 · Cited by 72 · see citing works
The use of selective serotonin reuptake inhibitors in eating disorders.
Mayer, L., & Walsh, B. T. (1998) · PubMed · Cited by 69 · see citing works
Selective Serotonin Reuptake Inhibitors
de Jonghe, F., & Swinkels, J. A. (1997) · CNS Drugs · doi:10.2165/00023210-199707060-00004 · Cited by 68 · see citing works
Goodwin, G. M. (1996) · PubMed · Cited by 68 · see citing works
Graeff, F. G. (1997) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70342-7 · Cited by 68 · see citing works
Somatic therapy for major depressive disorder: selection of an antidepressant.
Preskorn, S., & Burke, M. (1992) · PubMed · Cited by 67 · see citing works
Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects
de Vries, M. H., Raghoebar, M., Mathlener, I. S., & van Harten, J. (1992) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199212000-00010 · Cited by 66 · see citing works
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms
Spigset, O., Granberg, K., Hägg, S., Norström, Å., & Dahlqvist, R. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050261 · Cited by 66 · see citing works
Psychopharmacological treatment of social phobia.
Liebowitz, M. R., Gorman, J., Fyer, A. J., Campeas, R. B., Levin, A. P., Davies, S., & Df, K. (1985) · PubMed · Cited by 66 · see citing works
Arfken, C. L., Wilson, J. G., & Aronson, S. M. (2001) · International Psychogeriatrics · doi:10.1017/s1041610201007487 · Cited by 62 · see citing works
Response characteristics to antidepressants and placebo in post-traumatic stress disorder
Davidson, J. R. T., Malik, M. L., & Sutherland, S. N. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199711000-00001 · Cited by 62 · see citing works
Emslie, G. J., & Judge, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10945.x · Cited by 60 · see citing works
Strober, M. A., Freeman, R., DeAntonio, M., Lampert, C., & Diamond, J. (1997) · PubMed · Cited by 57 · see citing works
History of Serotonin and Serotonin Disorders
Sjoerdsma, A., & Palfreyman, M. G. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16869.x · Cited by 57 · see citing works
Greenblatt, D. J., Moltke, L. L., Schmider, J., Harmatz, J. S., & Shader, R. I. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04252.x · Cited by 57 · see citing works
Cole, M. G., Élie, L. M., McCusker, J., Bellavance, F., & Mansour, A. (2001) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198870101400109 · Cited by 57 · see citing works
Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
Koran, L. M., Jw, C., Ra, D., Rush, A. J., & Thiemann, S. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.11.1450 · Cited by 56 · see citing works
Paroxetine: pharmacokinetic and antidepressant effect in the elderly
Lundmark, J., Thomsen, I. S., Fjord‐Larsen, T., Manniche, P. M., Mengel, H. B., Møller‐Nielsen, E. M., Päuser, H., & Wålinder, J. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb07177.x · Cited by 56 · see citing works
Very High Cytochrome P4501A2 Activity and Nonresponse to Clozapine
Bender, S., & Eap, C. B. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.11.1048 · Cited by 56 · see citing works
Fluvoxamine in Civilians With Posttraumatic Stress Disorder
Davidson, J. R. T., Weisler, R. H., Malik, M. L., & Tupler, L. A. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199802000-00020 · Cited by 56 · see citing works
Non‐linear fluvoxamine disposition
Spigset, O., Granberg, K., Hägg, S., Söderström, E., & Dahlqvist, R. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00670.x · Cited by 54 · see citing works
Improved Efficacy and Fewer Side Effects Under Clozapine Treatment After Addition of Fluvoxamine
Szegedi, A., Wiesner, J., & Hiemke, C. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199504000-00012 · Cited by 53 · see citing works
A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders
Williams, R. B., Edwards, R. A., Newburn, G., Mullen, R., Menkes, D. B., & Segkar, C. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300730-00006 · Cited by 52 · see citing works
The Role of Metabolites of Antidepressants in the Treatment of Depression
Rudorfer, M. V., & Potter, W. Z. (1997) · CNS Drugs · doi:10.2165/00023210-199707040-00003 · Cited by 51 · see citing works
Walczak, D. D., Apter, J. T., Halikas, J. A., Borison, R. L., Carman, J. S., Post, G., PATRICK, R. O., Cohn, J. N., Cunningham, L. A., Rittberg, B. R., et al. (1996) · Annals of Clinical Psychiatry · doi:10.3109/10401239609147751 · Cited by 47 · see citing works
Fluoxetine versus trazodone in the treatment of outpatients with major depression.
Debus, J. R., Rush, A. J., Himmel, C., Tyler, D., Polatin, P. B., & Weissenburger, J. E. (1988) · PubMed · Cited by 41 · see citing works
Open Trial of Fluoxetine Therapy for Premenstrual Syndrome
Elks, M. L. (1993) · Southern Medical Journal · doi:10.1097/00007611-199305000-00003 · Cited by 41 · see citing works
A comparative trial of fluoxetine versus trazodone in outpatients with major depression.
Perry, P. J., Garvey, M. J., Kelly, M. W., Cook, B. L., Dunner, F. J., & Winokur, G. (1989) · PubMed · Cited by 40 · see citing works
In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine
Xu, Z., Xie, H., & Zhou, H. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.45319.x · Cited by 40 · see citing works
Aa, N. (1994) · PubMed · Cited by 40 · see citing works
Targeted pharmacotherapy in depression management
Preskorn, S. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199406003-00003 · Cited by 39 · see citing works
Substituting Carbamazepine with Oxcarbazepine Increases Citalopram Levels. A Report on Two Cases
Leinonen, E. V. J., Lepola, U. M., & Koponen, H. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-979563 · Cited by 38 · see citing works
Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review
Murphy, T. K., Bengtson, M. A., Tan, J. Y., Carbonell, E., & Levin, G. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200008002-00008 · Cited by 37 · see citing works
Pharmacologic Approaches in the Treatment of Eating Disorders
Jimerson, D. C., Herzog, D. B., & Brotman, A. W. (1993) · Harvard Review of Psychiatry · doi:10.3109/10673229309017063 · Cited by 36 · see citing works
Pharmacotherapy of bulimia nervosa and binge eating disorder: longer-term outcomes.
Ws, A. (1997) · PubMed · Cited by 34 · see citing works
Therapeutic monitoring of sertraline
Gupta, R., & Dziurdzy, S. A. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.3.498 · Cited by 33 · see citing works
Selective Serotonin Reuptake Inhibitors in the Treatment of Social Phobia
Ameringen, M. V., Mancini, C., Oakman, J. M., & Farvolden, P. (1999) · CNS Drugs · doi:10.2165/00023210-199911040-00006 · Cited by 32 · see citing works
Serotonin receptor and reuptake sites: pharmacologic significance.
Gonzalez–Heydrich, J., & Peroutka, S. J. (1990) · PubMed · Cited by 31 · see citing works
Levine, M., & Bellward, G. D. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06876-x · Cited by 31 · see citing works
Beyond specificity: Effects of serotonin and serotonergic treatments on psychobiological dysfunction
Dubovsky, S. L., & Thomas, M. (1995) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)00043-5 · Cited by 30 · see citing works
In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine
Xu, Z., Xie, H., & Zhou, H. (1996) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1996.tb00019.x · Cited by 30 · see citing works
Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin.
Rapeport, G., Muirhead, D. C., Williams, S. A., Cross, M. R., & Wesnes, K. A. (1996) · PubMed · Cited by 29 · see citing works
Core symptom pattern of social phobia
Fahl�n, T. (1996) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1996)4:5 · Cited by 29 · see citing works
Selective serotonin re-uptake inhibitors
LADER, M. H. (1992) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(92)90036-2 · Cited by 28 · see citing works
Care of depression in the elderly
Baumann, P. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199809005-00008 · Cited by 27 · see citing works
Kuhs, H., Schlake, H. ‐., Rolf, L. H., & Rudolf, G. A. E. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb10320.x · Cited by 26 · see citing works
Vythilingum, B., Cartwright, C., & Hollander, E. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200008002-00003 · Cited by 26 · see citing works
Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects
de Vries, M. H., van Harten, J., Bemmel, P. V., & Raghoebar, M. (1993) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510140403 · Cited by 25 · see citing works
Sertraline in underweight binge eating/purging‐type eating disorders: Five case reports
Frank, G., Kaye, W. H., & Marcus, M. D. (2001) · International Journal of Eating Disorders · doi:10.1002/eat.1048 · Cited by 25 · see citing works
Selective serotonin reuptake inhibitors for children and adolescents
Kastelic, E. A., Labellarte, M. J., & Riddle, M. A. (2000) · Current Psychiatry Reports · doi:10.1007/s11920-000-0055-x · Cited by 24 · see citing works
Update in the Pharmacotherapy of Depression
Sussman, N., & Stahl, S. M. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89538-1 · Cited by 24 · see citing works
Inpatient Treatment of Anorexia Nervosa: Review and Recommendations
Bowers, W. A., & Andersen, A. E. (1994) · Harvard Review of Psychiatry · doi:10.3109/10673229409017137 · Cited by 22 · see citing works
Therapeutic interchange of fluoxetine and sertraline: Experience in the clinical setting
Stock, A. J., & Kofoed, L. (1994) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/51.18.2279 · Cited by 21 · see citing works
Rw, F. (1986) · PubMed · Cited by 21 · see citing works
Beasley, C. M., Bosomworth, J. C., & Wernicke, J. F. (1990) · PubMed · Cited by 20 · see citing works
Are There Special Considerations in the Prescription of Serotonin Reuptake Inhibitors for Women?
Stewart, D. E. (1998) · The Canadian Journal of Psychiatry · doi:10.1177/070674379804300903 · Cited by 19 · see citing works
Long-term treatment of double depression: A preliminary study with serotonergic antidepressants
Hellerstein, D. J., Yanowitch, P., Rosenthal, J., Hemlock, C., Kasch, K. L., Samstag, L. W., & Winston, A. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90030-2 · Cited by 19 · see citing works
Selective Serotonin Reuptake Inhibitors in Pregnancy and Lactation
Gupta, S., Masand, P. S., & Rangwani, S. (1998) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199812000-00002 · Cited by 17 · see citing works
Use of SSRIs in the elderly: obvious benefits but unappreciated risks.
Herrmann, N. (2000) · PubMed · Cited by 16 · see citing works
Clinical experience with paroxetine in social anxiety disorder
Baldwin, D. S. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200007001-00005 · Cited by 16 · see citing works
Serotonin neuroscience discoveries usher in a new era of novel drug therapies for psychiatry.
Sm, S. (1992) · PubMed · Cited by 16 · see citing works
[Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
Étain, B., & Bonnet-Perrin, E. (2001) · PubMed · Cited by 15 · see citing works
Selective serotonin re-uptake inhibitors for children and adolescents
Ziervogel, C. F. (2000) · European Child & Adolescent Psychiatry · doi:10.1007/s007870070016 · Cited by 14 · see citing works
Speed of Onset of Action of the Newer Antidepressants—Fluoxetine and Bupropion
George, M. S., & Lydiard, R. B. (1991) · International Clinical Psychopharmacology · doi:10.1097/00004850-199100640-00002 · Cited by 12 · see citing works
Characteristics of fluvoxamine-induced nausea
Ueda, N., Yoshimura, R., Shinkai, K., Terao, T., & Nakamura, J. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00320-1 · Cited by 10 · see citing works
Marcus, E. R., & Bradley, S. S. (1990) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30361-7 · Cited by 4 · see citing works
Selective serotonin reuptake inhibitors (SSRIs) and falls in the elderly depressed patient.
Mort, J. R. (1999) · PubMed · Cited by 1 · see citing works
Flagged first, then by citations
5 of the 203 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579 · see citing works
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180 · see citing works
Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on
Carobrez, A. P., & Bertoglio, L. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.04.017 · Cited by 993 · see citing works
Desbonnet, L., Garrett, L., Clarke, G., Bienenstock, J., & Dinan, T. G. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.03.009 · Cited by 952 · see citing works
Hu, Z., Yang, X., Ho, P. C., Chan, S. Y., Heng, P. W. S., Chan, E., Duan, W., Koh, H., & Zhou, S. (2005) · Drugs · doi:10.2165/00003495-200565090-00005 · Cited by 664 · see citing works
Sleep disturbance as transdiagnostic: Consideration of neurobiological mechanisms
Harvey, A. G., Murray, G., Chandler, R. A., & Soehner, A. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.04.003 · Cited by 609 · see citing works
BDNF signaling in context: From synaptic regulation to psychiatric disorders
Wang, C. S., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell · doi:10.1016/j.cell.2021.12.003 · Cited by 629 · see citing works
Inflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609 · see citing works
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607 · see citing works
The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology
Martin, E. I., Ressler, K. J., Binder, E. B., & Nemeroff, C. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.004 · Cited by 132 · see citing works
The serotonin system in autism spectrum disorder: From biomarker to animal models
Muller, C. L., Anacker, A. M. J., & Veenstra-VanderWeele, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.010 · Cited by 531 · see citing works
Effect of sleep deprivation on the human metabolome
Davies, S. K., Ang, J. E., Revell, V. L., Holmes, B., Mann, A., Robertson, F. P., Cui, N., Middleton, B., Ackermann, K., Kayser, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402663111 · Cited by 527 · see citing works
Dendritic structural plasticity and neuropsychiatric disease
Forrest, M. P., Parnell, E., & Penzes, P. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.16 · Cited by 464 · see citing works
Ecological effects of pharmaceuticals in aquatic systems—impacts through behavioural alterations
Brodin, T., Piovano, S., Fick, J. B., Klaminder, J., Heynen, M., & Jonsson, M. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0580 · Cited by 501 · see citing works
Bauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H., & WFSBP Task Force on Unipolar Depres (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 474 · see citing works
Serotonin neurons in the dorsal raphe nucleus encode reward signals
Li, Y., Zhong, W., Wang, D., Feng, Q., Liu, Z., Zhou, J., Jia, C., Hu, F., Zeng, J., Guo, Q., et al. (2016) · Nature Communications · doi:10.1038/ncomms10503 · Cited by 420 · see citing works
50 years of hurdles and hope in anxiolytic drug discovery
Griebel, G., & Holmes, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4075 · Cited by 414 · see citing works
Atkin‐Smith, G. K., Tixeira, R., Paone, S., Mathivanan, S., Collins, C., Liem, M. K., Goodall, K. J., Ravichandran, K. S., Hulett, M. D., & Poon, I. K. H. (2015) · Nature Communications · doi:10.1038/ncomms8439 · Cited by 401 · see citing works
Zhu, C.-B., Lindler, K. M., Owens, A. W., Daws, L. C., Blakely, R. D., & Hewlett, W. A. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.116 · Cited by 317 · see citing works
The age of anxiety: role of animal models of anxiolytic action in drug discovery
Cryan, J. F., & Sweeney, F. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01362.x · Cited by 313 · see citing works
Porter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308 · see citing works
A genetically encoded sensor for measuring serotonin dynamics
Wan, J., Peng, W., Li, X., Qian, T., Song, K., Zeng, J., Deng, F., Hao, S., Feng, J., Zhang, P., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00823-7 · Cited by 293 · see citing works
Sehonová, P., Svobodová, Z., Doleželová, P., Vošmerová, P., & Faggio, C. (2018) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2018.03.076 · Cited by 279 · see citing works
Molecular and anatomical organization of the dorsal raphe nucleus
Huang, K. W., Ochandarena, N. E., Philson, A. C., Hyun, M., Birnbaum, J. E., Cicconet, M., & Sabatini, B. L. (2019) · eLife · doi:10.7554/elife.46464 · Cited by 267 · see citing works
Role of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257 · see citing works
“The serotonin system is one of the most widely studied neurotransmitter systems in depressive disorders (Vaswani et al , 2003) and its dysregulation by inflammatory cytokines could be one of the mechanisms underlying suicidal ideation and behavior (Oquendo et al , 2014).”
ENERGY INTAKE, MEAL FREQUENCY, AND HEALTH: A Neurobiological Perspective
Mattson, M. P. (2005) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.25.050304.092526 · Cited by 258 · see citing works
Pharmacokinetic Interactions of Drugs with St John’s Wort
Zhou, S., Chan, E., Pan, S. Q., Huang, M., & Lee, E. J. D. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104042632 · Cited by 256 · see citing works
Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders
Fakhoury, M. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9152-z · Cited by 248 · see citing works
Reversal of hippocampal neuronal maturation by serotonergic antidepressants
Kobayashi, K., Ikeda, Y., Sakai, A., Yamasaki, N., Haneda, E., Miyakawa, T., & Suzuki, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912690107 · Cited by 212 · see citing works
Escitalopram effects on insula and amygdala BOLD activation during emotional processing
Arce, E., Simmons, A. N., Lovero, K. L., Stein, M. B., & Paulus, M. P. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1004-8 · Cited by 198 · see citing works
Lattimore, K. A., Donn, S. M., Kaciroti, N., Kemper, A. R., Neal, C. R., & Vazquez, D. M. (2005) · Journal of Perinatology · doi:10.1038/sj.jp.7211352 · Cited by 189 · see citing works
Silva, L. J. G., Lino, C. M., Meisel, L. M., & Pena, A. (2012) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2012.08.021 · Cited by 181 · see citing works
McMahon, C. G., Althof, S. E., Kaufman, J. M., Buvat, J., Levine, S. B., Aquilina, J. W., Tesfaye, F., Rothman, M. L., Rivas, D. A., & Porst, H. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02097.x · Cited by 179 · see citing works
Pilot pharmacologic randomized controlled trial for psychogenic nonepileptic seizures
LaFrance, W. C., Jr., Keitner, G. I., Papandonatos, G. D., Blum, A. S., Machan, J. T., Ryan, C. E., & Miller, I. W. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f4d5a9 · Cited by 182 · see citing works
Jacobsen, J. P. R., & Mørk, A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.065 · Cited by 177 · see citing works
Walker, F. R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.10.002 · Cited by 175 · see citing works
Contributions of 5-HT2C receptors to multiple actions of central serotonin systems
Giorgetti, M., & Tecott, L. H. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.01.036 · Cited by 173 · see citing works
Current animal models of obsessive compulsive disorder: a critical review
Joel, D. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.006 · Cited by 168 · see citing works
The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology.
Martin, E. I., Ressler, K., Binder, E., & Nemeroff, C. (2010) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2010.07.006 · Cited by 494 · see citing works
Animal models of obsessive-compulsive disorder: Exploring pharmacology and neural substrates
Albelda, N. S., & Joel, D. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.04.006 · Cited by 163 · see citing works
Maculewicz, J., Kowalska, D., Świacka, K., Toński, M., Stepnowski, P., Białk‐Bielińska, A., & Dołżonek, J. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.149916 · Cited by 158 · see citing works
Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems
Birzniece, V., Bäckström, T. C., Johansson, I., Lindblad, C., Lundgren, P., Löfgren, M., Olsson, T., Ragagnin, G., Taube, M., Türkmen, Ş., et al. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.11.001 · Cited by 150 · see citing works
Narboux-Nême, N., Pavone, L. M., Avallone, L., Zhuang, X., & Gaspar, P. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.020 · Cited by 148 · see citing works
Anti-depressants, suicide, and drug regulation
Ludwig, J., & Marcotte, D. E. (2005) · Journal of Policy Analysis and Management · doi:10.1002/pam.20089 · Cited by 148 · see citing works
Dairy constituents and neurocognitive health in ageing
Camfield, D., Owen, L., Scholey, A. B., Pipingas, A., & Stough, C. K. K. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511000158 · Cited by 147 · see citing works
Silva, L. J. G., Pereira, A. M. P. T., Meisel, L. M., Lino, C. M., & Pena, A. (2014) · Environmental Pollution · doi:10.1016/j.envpol.2014.12.002 · Cited by 144 · see citing works
Romer, A. L., Knodt, A. R., Houts, R., Brigidi, B. D., Moffitt, T. E., Caspi, A., & Hariri, A. R. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.57 · Cited by 142 · see citing works
Stress risk factors and stress-related pathology: Neuroplasticity, epigenetics and endophenotypes
Radley, J. J., Kabbaj, M., Jacobson, L., Heydendael, W., Yehuda, R., & Herman, J. P. (2011) · Stress · doi:10.3109/10253890.2011.604751 · Cited by 140 · see citing works
Andersen, S. L., & Navalta, C. P. (2004) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.06.002 · Cited by 139 · see citing works
Hammack, S. E., Cooper, M. A., & Lezak, K. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.024 · Cited by 142 · see citing works
Correia, P. A., Lottem, E., Banerjee, D., Machado, A. S., Carey, M. R., & Mainen, Z. F. (2017) · eLife · doi:10.7554/elife.20975 · Cited by 138 · see citing works
Is increased antidepressant exposure a contributory factor to the obesity pandemic?
Lee, S. H., Paz-Filho, G., Mastronardi, C. A., Licinio, J., & Wong, M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.25 · Cited by 140 · see citing works
Bambico, F. R., Cassano, T., Domínguez-López, S., Katz, N., Walker, C. D., Piomelli, D., & Gobbi, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.80 · Cited by 139 · see citing works
Review: problems associated with long-term treatment with selective serotonin reuptake inhibitors
Moret, C., Isaac, M., & Briley, M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093582 · Cited by 135 · see citing works
McCauley, J. L., Olson, L. M., Dowd, M., Amin, T. T., Steele, A., Blakely, R., Folstein, S. E., Haines, J. L., & Sutcliffe, J. S. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20151 · Cited by 136 · see citing works
Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction
Cunningham, K. A., & Anastasio, N. C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.030 · Cited by 131 · see citing works
The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review
Olivier, J. D. A., Blom, T., Arentsen, T., & Homberg, J. R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.09.013 · Cited by 131 · see citing works
Mapping the genetic landscape across 14 psychiatric disorders
Grotzinger, A. D., Werme, J., Peyrot, W. J., Frei, O., de Leeuw, C., Bicks, L. K., Guo, Q., Margolis, M. P., Coombes, B. J., Batzler, A. J., et al. (2025) · Nature · doi:10.1038/s41586-025-09820-3 · Cited by 176 · see citing works
Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia
Angelucci, F., Mathé, A. A., & Aloe, L. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)46011-1 · Cited by 127 · see citing works
Xie, R., Jiang, P., Li, L., Jiang, J. H., Yu, B., Rao, J., Liu, H., Wei, W., & Qiao, Y. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.12.013 · Cited by 126 · see citing works
Early Life Stress, Depression And Parkinson’s Disease: A New Approach
Dallé, E., & Mabandla, M. V. (2018) · Molecular Brain · doi:10.1186/s13041-018-0356-9 · Cited by 124 · see citing works
Anxiety and Depression in Heart Failure: An Updated Review
Rashid, S., Qureshi, A. G., Noor, T. A., Yaseen, K., Sheikh, M. A. A., Malik, M. A., & Malik, J. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101987 · Cited by 123 · see citing works
Hodge, J. M., Wang, Y., Berk, M., Collier, F., Fernandes, T. J., Constable, M. J., Pasco, J. A., Dodd, S., Nicholson, G. C., Kennedy, R. L., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.003 · Cited by 122 · see citing works
A Review of Neurotransmitters Sensing Methods for Neuro-Engineering Research
Niyonambaza, S. D., Kumar, P., Xing, P., Mathault, J., Koninck, P. D., Boisselier, É., Boukadoum, M., & Miled, A. (2019) · Applied Sciences · doi:10.3390/app9214719 · Cited by 121 · see citing works
Rapamycin-inspired macrocycles with new target specificity
Guo, Z., Hong, S. Y., Wang, J., Rehan, S., Liu, W., Peng, H., Das, M., Li, W., Bhat, S., Peiffer, B., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0187-4 · Cited by 120 · see citing works
Ludwig, J., Marcotte, D. E., & Norberg, K. E. (2007) · Journal of Health Economics · doi:10.1016/j.jhealeco.2009.02.002 · Cited by 118 · see citing works
Williams, L. J., Henry, M. J., Berk, M., Dodd, S., Jacka, F. N., Kotowicz, M. A., Nicholson, G. C., & Pasco, J. A. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b3bb · Cited by 117 · see citing works
Bogaert, A. V. D., Sleegers, K., Zutter, S. D., Heyrman, L., Norrback, K., Adolfsson, R., Broeckhoven, C. V., & Del‐Favero, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1103 · Cited by 113 · see citing works
High-throughput evolution of near-infrared serotonin nanosensors
Jeong, S., Yang, D., Beyene, A. G., Bonis-O’Donnell, J. T. D., Gest, A. M. M., Navarro, N., Sun, X., & Landry, M. P. (2019) · Science Advances · doi:10.1126/sciadv.aay3771 · Cited by 112 · see citing works
Prenatal environmental risk factors for autism spectrum disorder and their potential mechanisms
Love, C., Sominsky, L., O’Hely, M., Berk, M., Vuillermin, P., & Dawson, S. L. (2024) · BMC Medicine · doi:10.1186/s12916-024-03617-3 · Cited by 110 · see citing works
Zirak, N., Shafiee, M., Soltani, G., Mirzaei, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27781 · Cited by 109 · see citing works
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
McNamara, R. K., & Lotrich, F. E. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.98 · Cited by 109 · see citing works
Methamphetamine-induced changes in the object recognition memory circuit
Reichel, C. M., Ramsey, L. A., Schwendt, M., McGinty, J. F., & See, R. E. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.11.003 · Cited by 106 · see citing works
Short- and Long-Term Functional Consequences of Fluoxetine Exposure During Adolescence in Male Rats
Iñiguez, S. D., Warren, B. L., & Bolaños‐Guzmán, C. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.033 · Cited by 104 · see citing works
Loading and delivery of sertraline using inorganic micro and mesoporous materials
Nunes, C. D., Vaz, P. D., Fernandes, A. C., Ferreira, P., Romão, C. C., & Calhorda, M. J. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.11.023 · Cited by 105 · see citing works
Vinkers, C. H., van Bogaert, M. J. V., Klanker, M., Korte, S. M., Oosting, R. S., Hanania, T., Hopkins, S. C., Olivier, B., & Groenink, L. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.097 · Cited by 104 · see citing works
Barim, A. Ö., Aydın, S., Çolak, R., Dağ, E., Deniz, O., & Şahin, İ. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.02.020 · Cited by 103 · see citing works
Carrillo, M., Ricci, L. A., Coppersmith, G., & Melloni, R. H. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1543-2 · Cited by 103 · see citing works
Sex differences in pharmacokinetics of antidepressants
Kokras, N., Dalla, C., & Papadopoulou‐Daifoti, Z. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.544250 · Cited by 102 · see citing works
Platelets and Anti-platelet Therapy
McNicol, A., & Israels, S. J. (2003) · Journal of Pharmacological Sciences · doi:10.1254/jphs.93.381 · Cited by 102 · see citing works
Selective serotonin reuptake inhibitors as a novel class of immunosuppressants
Gobin, V., Steendam, K. V., Denys, D. A. J. P., & Deforce, D. L. D. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.02.030 · Cited by 102 · see citing works
Drugs that Disturb Sleep and Wakefulness
Schweitzer, P. K., & Randazzo, A. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-24288-2.00045-3 · Cited by 100 · see citing works
Sullivan, P. W., Valuck, R. J., Saseen, J. J., & MacFall, H. M. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00006 · Cited by 97 · see citing works
Selective Serotonin Reuptake Inhibitors Affect Neurobehavioral Development in the Human Fetus
Mulder, E. J. H., Ververs, T. F., de Heus, R., & Visser, G. H. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.67 · Cited by 96 · see citing works
McGrath-Hanna, N. K., Greene, D. M., Tavernier, R. J., & Bult‐Ito, A. (2003) · International Journal of Circumpolar Health · doi:10.3402/ijch.v62i3.17560 · Cited by 91 · see citing works
Amireault, P., & Dubé, F. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.104.039313 · Cited by 90 · see citing works
Chen, P., Hei, M., Kong, L., Liu, Y., Yu, Y., Mu, H., Zhang, X., Zhao, S., & Duan, J. (2019) · Food & Function · doi:10.1039/c9fo01178a · Cited by 89 · see citing works
McNamara, R. K. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i1.15 · Cited by 88 · see citing works
Effects of orally administered lavender essential oil on responses to anxiety‐provoking film clips
Bradley, B. F., Brown, S. L., Chu, S., & Lea, R. W. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1016 · Cited by 86 · see citing works
Nelson, E. M., & Philbrick, A. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q748 · Cited by 86 · see citing works
Theodoridi, A., Tsalafouta, A., & Pavlidis, M. A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00223 · Cited by 85 · see citing works
Thompson, M. R., Li, K. M., Clemens, K. J., Gurtman, C. G., Hunt, G. E., Cornish, J. L., & McGregor, I. S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300347 · Cited by 85 · see citing works
Improved green and red GRAB sensors for monitoring spatiotemporal serotonin release in vivo
Deng, F., Wan, J., Li, G., Dong, H., Xia, X., Wang, Y., Li, X., Zhuang, C., Zheng, Y. R., Liu, L. D., et al. (2024) · Nature Methods · doi:10.1038/s41592-024-02188-8 · Cited by 93 · see citing works
Current animal models of obsessive compulsive disorder: an update
Albelda, N. S., & Joel, D. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.070 · Cited by 81 · see citing works
McNamara, R. K., Strimpfel, J., Jandacek, R. J., Rider, T., Tso, P., Welge, J. A., Strawn, J. R., & DelBello, M. P. (2014) · PharmaNutrition · doi:10.1016/j.phanu.2014.02.002 · Cited by 81 · see citing works
Drug discovery: selecting the optimal approach
Sams‐Dodd, F. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.03.015 · Cited by 81 · see citing works
Simmons, A. N., Arce, E., Lovero, K. L., Stein, M. B., & Paulus, M. P. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990149 · Cited by 80 · see citing works
Stenkrona, P., Halldin, C., & Lundberg, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.002 · Cited by 78 · see citing works
Mullins, C. D., Shaya, F. T., Meng, F., Wang, J., & Harrison, D. J. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.5.660.63590 · Cited by 78 · see citing works
Chechko, N., Wehrle, R., Erhardt, A., Holsboer, F., Czisch, M., & Sämann, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005537 · Cited by 76 · see citing works
- Authors
- Vaswani, M., Linda, F. K., & Ramesh, S.
- Affiliations
- All India Institute of Medical Sciences (IN)
- Corresponding author
- Vaswani, Meera
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2003-02
- Volume
- 27
- Issue
- 1
- Pages
- 85-102
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W1988612597
- Cited by
- 612
- References
- 203
- Citations by year
- 2026: 16 · 2025: 17 · 2024: 20 · 2023: 30 · 2022: 19 · 2021: 30 · 2020: 10 · 2019: 22 · 2018: 28 · 2017: 27 · 2016: 23 · 2015: 37 · 2014: 24 · 2013: 29 · 2012: 27
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- selective serotonin reuptake inhibitors, serotonin, serotonin receptors, antidepressant mechanism, adverse drug reactions, drug-drug interactions, cytochrome P450, therapeutic drug monitoring, tricyclic antidepressants, depression, obsessive-compulsive disorder, social anxiety disorder, anorexia nervosa, bulimia nervosa, eating disorders, sleep disorders
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Anxiety Disorders, Feeding and Eating Disorders, Child, Depressive Disorder, Female, Humans, Male, Middle Aged, Pregnancy, Pregnancy Complications, Substance Withdrawal Syndrome, Suicide, Attempted, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review